

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6026850

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ALAN D AGULNICK	11/25/2014
KEVIN D'AMOUR	04/24/2019
RECEIVING PARTY DATA	
Name:	VIACYTE, INC.
Street Address:	3550 GENERAL ATOMICS COURT
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16452415
CORRESPONDENCE DATA	
Fax Number:	(858)207-5002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	8582070484
Email:	pdewhurst@viacyte.com
Correspondent Name:	PATTY DEWHURST
Address Line 1:	3550 GENERAL ATOMICS COURT
Address Line 4:	SAN DIEGO, CALIFORNIA 92121
ATTORNEY DOCKET NUMBER:	9511-96315-06
NAME OF SUBMITTER:	PATTY DEWHURST
SIGNATURE:	/Patty Dewhurst/
DATE SIGNED:	03/23/2020
This document serves as an Oath/Declaration (37 CFR 1.63).	
Total Attachments: 4	
source=9511-96315-06_Agulnick_Assignment#page1.tif	
source=9511-96315-06_Agulnick_Assignment#page2.tif	
source=9511-96315-06_DAmour_Assignment#page1.tif	
source=9511-96315-06_DAmour_Assignment#page2.tif	

ASSIGNMENT
(Patent Application)

I, the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) or design patent application entitled

“IN VITRO DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO PANCREATIC ENDODERM CELLS (PEC) AND ENDOCRINE CELLS,”

filed with the U.S. Patent & Trademark Office on December 13, 2013

and assigned serial no. 14/106,330; and

“IN VITRO DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO PANCREATIC ENDODERM CELLS (PEC) AND ENDOCRINE CELLS,”

filed with the U.S. Patent & Trademark Office on August 8, 2014

and assigned serial no. 14/455,059.

For one dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which I acknowledge, I:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to ViaCyte, Inc., a corporation of the State of Delaware having a principal place of business at 3550 General Atomics Court, San Diego, CA 92121 (“Assignee”), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;

ASSIGNMENT

Attorney Docket Nos. 96183-001910US-893057

and 96183-001920US-914336

Page 2 of 2

- (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon me, as well as my heirs, legal representatives, and assigns.
5. Promise and affirm that I have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the date indicated beside my signature.

Signature: _____

Alan D. Agulnick

Date: _____

11/25/2014

ASSIGNMENT

WHEREAS, I, Kevin D'Amour, of San Diego, CA, have invented certain inventions, as described in the following:

U.S. Patent Application No. 14/106,330, filed on December 13, 2013, issued as U.S.

Patent No. 8,859,286, entitled "IN VITRO DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO PANCREATIC ENDODERM CELLS (PEC) AND ENDOCRINE CELLS;"

U.S. Patent Application No. 14/455,059, filed on August 8, 2014, issued as U.S. Patent No. 9,650,610, entitled "IN VITRO DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO PANCREATIC ENDODERM CELLS (PEC) AND ENDOCRINE CELLS;" and

U.S. Patent Application No. 15/478,094, filed on April 3, 2017, entitled "METHODS FOR PRODUCING HORMONE SECRETING CELLS IN A SUBJECT."

which are collectively referred to as "the patent applications."

WHEREAS, ViaCyte, Inc., a corporation organized under the laws of the State of Delaware, having a place of business at 3550 General Atomics Court, Suite 02-503, San Diego, CA 92121, desires to acquire an interest therein:


NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, I, Kevin D'Amour hereby sell, assign and transfer to ViaCyte, Inc., the full and exclusive right, title and interest in and to said invention, the patent applications and patent rights throughout the world, including foreign patent priority rights, the right to file and prosecute International Applications under the Patent Cooperation Treaty, and the right to file and prosecute applications under the European Patent Convention; said invention, the patent applications and letters patent in this or any foreign country, and all corresponding non-provisional applications, divisions, continuations, continuations-in-part, reissues and extensions thereof, to be held and enjoyed by ViaCyte, Inc., for its own use and benefit, and for its successors and assigns to the full end of the term for which letters patent may be granted by the United States or any foreign country, as fully and entirely as the same would have been held by me had this assignment and sale not been made, and covenant that I have full right so to do, and

agree that I will communicate to ViaCyte, Inc., or its successors and assigns, any facts known to me respecting said invention, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths, and do everything possible to aid ViaCyte, Inc., its successors and assigns to obtain and enforce proper patent protection for said invention in the United States or any foreign country.

I confirm that at the time the invention was made, I was under an obligation to assign the invention to ViaCyte, Inc.

I hereby grant the law firm of Klarquist Sparkman, LLP, the power to insert on this Assignment any further information which may be necessary or desirable in order to comply with all applicable legal requirements, including the rules of the United States Patent and Trademark Office, for submitting and recording this document.

Executed at the place and date opposite my signature below.


Kevin D'Amour


STATE OF California)
COUNTY OF San Diego) ss.

On April 24, 2019, before me, Patricia L. Dewhurst, Notary Public, personally appeared Kevin D'Amour, who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/~~she~~/they executed the same in his/~~her~~/their authorized capacity(ies), and that by his/~~her~~/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

[SEAL]




Signature of Notary Public